[an error occurred while processing this directive]
C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Support
Latest News
Business
Government & Policy
Science/Technology
Careers and Employment
ACS News
topics
   
Support
 
Support
How to log in
Contact Us
Site Map
   
About C&EN
About the Magazine
How to Subscribe
How to Advertise
Chemcyclopedia

Latest News RSS Feed

latest news RSS feedWhat is this?

   
Join ACS
Join ACS
  Latest News  
  October 25,  2004
Volume 82, Number 43
p. 13
 

BIOTERRORISM

  Biodefense Seen As Falling Short
Survey says U.S. is ill prepared to rapidly respond to biothreats
 

MARC REISCH
   
 
 
8243NOTW3_Neumune
IN THE WORKS Hollis-Eden's Neumune is intended to protect against radiation damage after a nuclear attack. -

HOLLIS-EDEN PHOTO

Biomedical experts from the pharmaceutical industry, government, and academia generally agree that the U.S. is poorly prepared to quickly develop the medicines needed to counter bioterrorism and natural epidemics, according to a new survey.

Researchers from the Center for Biosecurity at the University of Pittsburgh Medical Center and from technology research firm Sarnoff Corp. just published the results of their poll in a report called "Taking the Measure of Countermeasures: Leaders' Views on the Nation's Capacity to Develop Biodefense Countermeasures." The report is available on the Internet at http://www.upmc-biosecurity.org.

The Project Bioshield Act of 2004, which provides $5.6 billion over the next 10 years to stockpile biodefense drugs and vaccines, "will not be enough to entice pharmaceutical industry leaders into this field," the report's authors say.

The survey calls for a single organization that would monitor biodefense strategy and coordinate collaboration among academic, pharmaceutical, biotech, and government entities.

"An engineered pathogen is almost trivially easy to engineer," says Lynne Gilfillan, government operation director at Sarnoff and a report coauthor. "We need an organization whose primary focus is to reduce the time to develop new drugs. Government needs to be involved."

Richard B. Hollis, CEO of the venture-capital-funded firm Hollis-Eden Pharmaceuticals, counters that "the report is ludicrous. It says the taxpayers should take all the research risk and then pay for the new drugs."

Hollis, whose firm is developing immune-regulating hormones intended to protect victims of a nuclear or dirty-bomb attack, says the government needs a central clearinghouse to define what it needs under Project Bioshield. It must then "invite firms with novel technology to spend their own development funds and compete to offer the best products to the government."

 
     
  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2004
 


 
Related Stories
Countering Bioterrorism
[C&EN, Aug. 16, 2004]
E-mail this article
to a friend
Print this article
E-mail the editor